COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?

N. Silvestris, M. Di Maio, A. Russo, R. Chiari, U. De Giorgi, L. Del Mastro, D. Giuffrida, N. La Verde, F. Perrone, M. Tucci, G. D. Beretta, S. Cinieri

Research output: Contribution to journalReview articlepeer-review

Abstract

High mortality rates in elderly patients or in those with underlying chronic illnesses and/or a compromised immune system is a peculiar feature of COVID-19 infection. The possible coexistence of a cancer and COVID-19 infection in the same individual prompted concerns regarding their synergistic effect on prognosis. In order to balance patients' needs with the risks related to the infection, the question oncologists have asked from the beginning of the first wave of the pandemic has been: 'how can we deal with COVID-19 infection in cancer patients?' In pursuing its mission, the Associazione Italiana Oncologia Medica (AIOM) has made every possible effort to support cancer patients, health care professionals and institutions in the decision-making processes the pandemic has engendered within this scenario. The relevant documents as well as the educational and institutional initiatives the AIOM has taken are reported in this article.

Original languageEnglish
Pages (from-to)100100
Number of pages1
JournalESMO Open
Volume6
Issue number2
DOIs
Publication statusPublished - Apr 1 2021

Keywords

  • AIOM
  • cancer
  • COVID-19
  • treatment
  • vaccination

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?'. Together they form a unique fingerprint.

Cite this